9-28 | Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB.
9-19 | Ahead of the global tuberculosis High-Level Meeting at the United Nations, MSF calls on Johnson & Johnson not to enforce any secondary patents for bedaquiline in any country with a high burden of TB.We also call on Cepheid to drop the price of the GeneXpert TB test from US$10 to US$5 in order to save lives.
7-6 | After four years of caring for patients with multidrug-resistant tuberculosis in Somaliland, Médecins Sans Frontières/Doctors Without Borders (MSF) is handing over its project to the Ministry of Health Development. When nine-year-old Mohamed fell ill, sweating heavily at night and coughing, his mother, Sabah, took him to the nearest hospital. He was misdiagnosed and the drugs he was prescribed had no effect. “He was prescribed some injectable drugs, but they didn’t work,” recalls Sabah. “He was not improving.”
5-17 | Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB-PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World Health Organization (WHO) have announced it will update global guidance on treatment. Following the results of MSF’s trial the WHO are now recommending programmatic use of the 6- month BPaLM regimen – comprising bedaquiline, pretomanid, linezolid (600 mg) and moxifloxacin in MDR-TB patients in pla
5-17 | Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB-PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World Health Organization (WHO) have announced it will update global guidance on treatment. Following the results of MSF’s trial the WHO are now recommending programmatic use of the 6- month BPaLM regimen – comprising bedaquiline, pretomanid, linezolid (600 mg) and moxifloxacin in MDR-TB patients in pla